Introduction
Fascioliasis is a rare parasitic infection primarily affecting the hepatobiliary system, caused by one of 2 digenean flatworms, Fasciola hepatica or Fasciola gigantica, commonly referred to as liver flukes.[1] F gigantica lives mainly in tropical climates, while F hepatica is found in temperate climates. They are parasites of many types of plant-eating animals, and their larvae are found on aquatic vegetation.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Adult Fasciola hepatica flukes grow to become spiny-appearing, brown, leaf-shaped, flatworms, typically around 30 mm by 15 mm in size and easily seen with the naked eye. Anteriorly, they have 2 suckers, a large one on the ventral side referred to as the acetabulum that allows the fluke to suction itself to the wall of the bile duct and remain in place so the smaller, more anterior sucker may feed on the bile.[2] As their name implies, Fasciola gigantica flatworms can grow up to 75 mm in length but are otherwise similar in appearance to their smaller counterparts.[3][4]
Regardless of whether the host is bovine or human, the life cycle remains the same. Adult liver flukes release unembryonated eggs into their host’s bile ducts, which then pass into their stools. The host defecates in the environment near or within a pond or stream. Eggs become embryonated when they reach a water source and hatch into free-swimming miracidia that seek out an intermediate host, one of several species of amphibious snail. The miracidium will bore directly into the snail's tissues. Once inside, miracidia go through several metamorphoses, first becoming sporocysts that give rise to mother rediae, which in turn produce daughter rediae. Germ balls develop inside the daughter rediae that become cercariae, which will grow and bore back out of the snail to again become free-swimming in the environment. They encyst as metacercariae on aquatic vegetation and are eaten by their definitive host.[5]
Flatworms most commonly cause infection in humans when humans eat vegetation contaminated with metacercariae, such as watercress. Metacercariae excyst in the duodenum, as they do in the snail, and penetrate through the intestinal wall into the peritoneum. From there, they migrate cephalad, boring through the parenchyma of the liver before finally settling in the biliary ducts. In 3 to 4 months, they develop into adults, occupying the large biliary ducts primarily and laying more than 20,000 eggs per day. Adults can live up to 13 years in a human host if untreated.[2]
The migrating metacercariae cause parenchymal liver damage, triggering a cascade of inflammatory and immune responses that lead to a constellation of acute symptoms. Adult flukes may partially or completely obstruct the bile ducts, over time causing fibrosis, hypertrophy, and later dilation of the proximal biliary tree. Parasite load is typically positively correlated with the degree of liver damage.[1]
Epidemiology
The global prevalence of Fasciola infection is estimated at between 2.4 and 17 million and is typically underreported and underdiagnosed. In the United States, sporadic cases are seen mainly in travelers and immigrants. Disease in cattle and other livestock is more prevalent in the United States and varies by geographic location.[6][7] Fasciola hepatica is endemic to Europe and Asia, occasionally seen in Northern Africa, Central and South America, and the Middle East, and sporadic cases rarely occur in the United States and the Caribbean.[8] Fasciola gigantica infects domestic livestock across Asia, the Pacific Islands, and some parts of Northern Africa.[3] In parts of Africa and Asia, the 2 species overlap, and their clinical presentations are indistinguishable. Cattle and sheep are the most common definitive hosts, but the flatworms often infect several other grazing animals in the wild. Humans who live in regions where cattle and sheep industries are prominent and who consume raw aquatic vegetation, particularly watercress, are at the highest risk of contracting the parasite.[1]
History and Physical
There are 2 distinct phases of fascioliasis.
The acute (hepatic) phase usually begins 6 to 12 weeks after ingestion of metacercariae from a contaminated water source. The first sign is usually very high fever, followed by right upper quadrant pain, hepatomegaly, and occasionally jaundice. A complete blood count differential will show a marked peripheral eosinophilia. Patients often present with associated myalgias, urticarial rash, nausea, anorexia, and diarrhea. These symptoms are attributed to Fasciola flatworms migrating through the liver parenchyma and triggering inflammatory and immune responses along the way. Additional laboratory diagnostic clues include transaminitis, anemia, elevated erythrocyte sedimentation rate, and hypergammaglobulinemia. Early complications are rare but may be seen with high parasite load and include ascites, hemobilia, subcapsular hematomas, and rarely severe parenchymal liver necrosis. However, in most cases, acute symptoms resolve within 6 weeks, and the infection enters the chronic phase.[1]
Early extrahepatic manifestations are typically type III (immune complex deposition) or type IV (IgE)-mediated hypersensitivity. A reactive eosinophilic pneumonitis is nonspecific for helminth infections and is well described in the literature.[9] Overwhelming activation of the host’s immune system and inflammatory response can cause vasculitis. In the heart, this can lead to myocarditis, which in turn can cause cardiac conduction abnormalities. In the brain, cerebral vasculitis may lead to focal neurologic deficits or seizures, but these are all highly uncommon. Generalized lymphadenopathy is often present.[1]
The chronic (biliary) phase usually begins about 6 months after the acute infection, once the flukes have settled into the bile ducts, and may last for a decade or more. This phase is usually asymptomatic but occasionally can present as chronic epigastric and right upper quadrant pain, nausea, vomiting, diarrhea, hepatomegaly, jaundice, and failure to thrive. Peripheral eosinophilia is unlikely to be present. Chronic common bile duct obstructions may develop and lead to recurrent jaundice, cholelithiasis, pancreatitis, and, more seriously, ascending cholangitis. Prolonged infection and/or high parasite load lead to chronic hepatobiliary damage and can result in chronic biliary cirrhosis, sclerosing cholangitis, and even cholangiocarcinoma.[1][10][11]
The migration of Fasciola from the intestine into the liver is not always complete. Ectopic fascioliasis is the term for infection occurring outside the hepatobiliary system. They may migrate to almost any part of the body. Their presence results in localized mononuclear eosinophilic infiltration that causes secondary tissue damage due to the host’s immune response. Frequently, they are located in the subcutaneous tissue of the abdominal wall, but they may also migrate to the peritoneum, intestinal wall, lungs, heart, brain, muscles, or eyes. Traveling flatworms under the skin or fat tissue leave behind migrating, pruritic, erythematous, painful nodules 1 cm to 6 cm in diameter and may be seen or palpated. Occasionally, nodules can become infected and turn into a local abscess.[1][12][13][14][15] Another rare form of ectopic fascioliasis is Halzoun syndrome or pharyngeal fascioliasis. This condition is sometimes seen in the Middle East in areas where people eat raw liver. In this case, the metacercariae, or young adult flukes, living in the ingested liver attach to the mucosa of the upper respiratory or digestive tract, causing pharyngitis or esophagitis. Rarely, edema and swelling of the upper airway can be so severe that patients have asphyxiated.[16]
Evaluation
Fascioliasis is exceedingly rare in the United States, but should be on the differential for any patient with the combination of abdominal pain (especially right upper quadrant), transaminitis, and marked peripheral eosinophilia. Even greater suspicion should arise if a patient has traveled to endemic areas in Europe, Asia, or the Pacific and their dietary history includes ingestion of watercress or raw vegetables washed in potentially contaminated water. Often, there is a delay in the diagnosis of this disease, even in endemic areas, due to its rarity and nonspecific acute symptoms.[2][17]
Serology has become the fastest and most efficient method for testing for fascioliasis in recent years. Titers against Fasciola antigens become positive during the early phase of parasite migration and are detectable for 2 to 4 weeks following initial exposure to the host’s immune system. Enzyme-linked immunosorbent assay (ELISA) techniques have largely replaced stool ova and parasite testing because of their rapid turnaround, sensitivity, and quantitative capability.[18][19] Serum Fasciola antigen levels often correlate with the degree of infection.[20] Five to 7 weeks after the initial infection, the adult worms are mature enough to produce eggs; thus, there are no eggs in stool during the acute phase of the infection. Antigen levels positively correlate with the infectious burden. Successful treatment and eradication of the parasites correlate with a decline in ELISA titers against Fasciola antigens. Antibodies may still be detectable at low levels for years. The assay becomes undetectable in approximately 65% of patients one month following successful treatment. Some patients will have a low positive titer for life without any evidence of active infection.[21][22]
Microscopic examination of stool or duodenal bile aspirates for eggs remains useful for detecting chronic infections in rural or third-world settings where resources may be scarce. They are also sometimes found incidentally while working up biliary obstructions. Fasciola hepatica eggs are yellow-brown and ovoid, measuring 130 to 150 micrometers long by 60 to 90 micrometers wide. A single adult fluke can release over 20,000 eggs per day, but that release is intermittent. Thus, an examination of multiple stool or duodenal aspirate specimens may be needed, as a single negative result does not necessarily exclude the diagnosis.[23]
Rarely, one might also identify adult flukes in the biliary tree on endoscopic retrograde cholangiopancreatography in a patient with biliary obstruction. Occasionally, capsular liver nodules may be seen by a surgeon during a diagnostic laparoscopy, but in the absence of additional clinical history, they are nonspecific. Liver biopsy is not routinely warranted, as serology is much more specific, sensitive, and cost-effective.[24]
A computerized tomography scan may show multiple, small (approximately 25 mm in diameter), nodular, branching, subcapsular lesions in the liver parenchyma. These tortuous tracks are left behind by the migrating parasites. Necrotic areas may be seen on scans using intravenous contrast.[24][25][26] Subcapsular hematoma, capsular thickening, or parenchymal calcifications can also be seen.[27] Ultrasonography, cholangiogram, and endoscopic retrograde cholangiopancreatography are helpful during the biliary stage and may show mobile, leaf-like flukes in the biliary ducts or gallbladder, often associated with stones. Irregular thickening of the common bile duct wall, hepatomegaly, splenomegaly, or periportal lymphadenopathy are often present, especially in the acute phase.[24]
Treatment / Management
The treatment of choice is oral triclabendazole 10 mg/kg daily taken after a meal for 2 days. Triclabendazole is an imidazole derivative that prevents the polymerization of tubulin into microtubules, rendering cells incapable of producing their cytoskeletal structures. This medication is effective against all stages of fascioliasis with a cure rate of over 90%.[28][29] Fasciola species do not respond well to ivermectin, praziquantel, artesunate, mebendazole, or albendazole.[30] When a patient is diagnosed with fascioliasis, other family or house members should be tested for serum Fasciola antigens. Treatment is warranted when a patient has a positive test result, regardless of symptoms, to reduce the risk of future complications.(B3)
Differential Diagnosis
Acute hepatitis, autoimmune hepatitis, and shock liver will all have very significantly elevated transaminases, typically in the thousands. These level are much higher than the levels seen in fascioliasis, which are usually in the hundreds. Toxocariasis, acute schistosomiasis, ascariasis, and strongyloidiasis are nearly indistinguishable from fascioliasis in the acute phase, especially when accompanied by peripheral eosinophilia and pulmonary symptoms. Serologic testing is required to rule these out.
Prognosis
Once fascioliasis is diagnosed, the prognosis is excellent. Triclabendazole is effective against all stages of fascioliasis, with a cure rate of more than 90%.[28][29]
Complications
Chronic infections can be complicated by ascending cholangitis, which requires intravenous antibiotics and usually surgery. Biliary obstruction due to parasites in the setting of ascending cholangitis requires emergency endoscopic retrograde cholangiopancreatography to directly remove the worms from the common bile duct, if possible. Chronic infections lead to chronic biliary inflammation and destruction, giving rise to sclerosing cholangitis, biliary cirrhosis, and cholangiocarcinoma.[5][10][11]
Deterrence and Patient Education
Follow-up after treatment should assess for a decrease in serologic titers, resolution of eosinophilia, and clearance of eggs in the stool. It is reasonable to repeat all positive test results at 3 months posttreatment. Resolution of biliary findings on ultrasonography after therapy may also be helpful if the patient presented with biliary obstruction, as scar tissue and biliary duct thickening may still be present and can cause prolonged symptoms.[31] When a patient is diagnosed with fascioliasis, other family or house members should be tested for serum fasciola antigens. Any patient who has a positive test result, regardless if they are symptomatic or not, should be treated to avoid the risk of future complications.
Infection can be prevented by educating patients to avoid ingestion of raw freshwater plants, especially in endemic areas. Elimination of snail intermediates has been attempted in endemic areas in the past but is not practical. No vaccines are available for humans, and the disease is much too rare in the human population for a vaccine to be economically viable.
Enhancing Healthcare Team Outcomes
Management of fascioliasis starts with early recognition of this disease that often goes undiagnosed. Diagnosis requires a high degree of suspicion and an understanding that serologic evaluation is the most beneficial and cost-effective method for assessing the disease.[17] Coordination of care requires an interprofessional team of healthcare providers that includes clinicians, often primary care hospitalists, along with gastroenterologists and often infectious disease specialists. Nurses, laboratory technicians, and pharmacists also play a role in handling and evaluating specimens and delivering patient care.[28]
Media
(Click Image to Enlarge)
References
Arjona R, Riancho JA, Aguado JM, Salesa R, González-Macías J. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine. 1995 Jan:74(1):13-23 [PubMed PMID: 7837967]
Level 3 (low-level) evidenceKaya M, BeÅŸtaÅŸ R, Cetin S. Clinical presentation and management of Fasciola hepatica infection: single-center experience. World journal of gastroenterology. 2011 Nov 28:17(44):4899-904. doi: 10.3748/wjg.v17.i44.4899. Epub [PubMed PMID: 22171131]
Level 3 (low-level) evidenceSoliman MF. Epidemiological review of human and animal fascioliasis in Egypt. Journal of infection in developing countries. 2008 Jun 1:2(3):182-9 [PubMed PMID: 19738348]
Level 3 (low-level) evidenceMarcilla A, Bargues MD, Mas-Coma S. A PCR-RFLP assay for the distinction between Fasciola hepatica and Fasciola gigantica. Molecular and cellular probes. 2002 Oct:16(5):327-33 [PubMed PMID: 12477436]
Level 3 (low-level) evidenceHawramy TA, Saeed KA, Qaradaghy SH, Karboli TA, Nore BF, Bayati NH. Sporadic incidence of Fascioliasis detected during hepatobiliary procedures: a study of 18 patients from Sulaimaniyah governorate. BMC research notes. 2012 Dec 21:5():691. doi: 10.1186/1756-0500-5-691. Epub 2012 Dec 21 [PubMed PMID: 23259859]
Level 3 (low-level) evidenceWeisenberg SA, Perlada DE. Domestically acquired fascioliasis in northern California. The American journal of tropical medicine and hygiene. 2013 Sep:89(3):588-91. doi: 10.4269/ajtmh.13-0069. Epub 2013 Jul 8 [PubMed PMID: 23836562]
Level 3 (low-level) evidenceMas-Coma S, Valero MA, Bargues MD. Chapter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Advances in parasitology. 2009:69():41-146. doi: 10.1016/S0065-308X(09)69002-3. Epub [PubMed PMID: 19622408]
Level 3 (low-level) evidenceMas-Coma S. Epidemiology of fascioliasis in human endemic areas. Journal of helminthology. 2005 Sep:79(3):207-16 [PubMed PMID: 16153314]
Level 3 (low-level) evidenceBayhan Gİ, Batur A, Taylan-Özkan A, Demirören K, Beyhan YE. A pediatric case of Fascioliasis with eosinophilic pneumonia. The Turkish journal of pediatrics. 2016:58(1):109-112 [PubMed PMID: 27922247]
Level 3 (low-level) evidenceAl Qurashi H, Masoodi I, Al Sofiyani M, Al Musharaf H, Shaqhan M, All GN. Biliary fascioliasis--an uncommon cause of recurrent biliary colics: report of a case and brief review. German medical science : GMS e-journal. 2012:10():Doc10. doi: 10.3205/000161. Epub 2012 May 2 [PubMed PMID: 22566787]
Level 3 (low-level) evidencePrueksapanich P, Piyachaturawat P, Aumpansub P, Ridtitid W, Chaiteerakij R, Rerknimitr R. Liver Fluke-Associated Biliary Tract Cancer. Gut and liver. 2018 May 15:12(3):236-245. doi: 10.5009/gnl17102. Epub [PubMed PMID: 28783896]
Tanir G, Karaman A, Tüfekçı SB, ErdoÄŸan D, Tuygun N, Ozkan AT. A case of ectopic intraabdominal fascioliasis presented with acute abdomen. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology. 2011 Jun:22(3):347-50 [PubMed PMID: 21805430]
Level 3 (low-level) evidenceKim AJ, Choi CH, Choi SK, Shin YW, Park YK, Kim L, Choi SJ, Han JY, Kim JM, Chu YC, Park IS. Ectopic Human Fasciola hepatica Infection by an Adult Worm in the Mesocolon. The Korean journal of parasitology. 2015 Dec:53(6):725-30. doi: 10.3347/kjp.2015.53.6.725. Epub 2015 Dec 31 [PubMed PMID: 26797440]
Mas-Coma S, Agramunt VH, Valero MA. Neurological and ocular fascioliasis in humans. Advances in parasitology. 2014:84():27-149. doi: 10.1016/B978-0-12-800099-1.00002-8. Epub [PubMed PMID: 24480313]
Level 3 (low-level) evidenceMusa D, Godbole G, Chiodini PL, Phillips R. Unusual case of a lung abscess. BMJ case reports. 2013 Apr 16:2013():. doi: 10.1136/bcr-2012-008306. Epub 2013 Apr 16 [PubMed PMID: 23595175]
Level 3 (low-level) evidenceSaleha AA. Liver fluke disease (fascioliasis): epidemiology, economic impact and public health significance. The Southeast Asian journal of tropical medicine and public health. 1991 Dec:22 Suppl():361-4 [PubMed PMID: 1822928]
Level 3 (low-level) evidenceCabada MM, White AC Jr. New developments in epidemiology, diagnosis, and treatment of fascioliasis. Current opinion in infectious diseases. 2012 Oct:25(5):518-22. doi: 10.1097/QCO.0b013e3283567b7e. Epub [PubMed PMID: 22744320]
Level 3 (low-level) evidenceEspinoza JR, Maco V, Marcos L, Saez S, Neyra V, Terashima A, Samalvides F, Gotuzzo E, Chavarry E, Huaman MC, Bargues MD, Valero MA, Mas-Coma S. Evaluation of Fas2-ELISA for the serological detection of Fasciola hepatica infection in humans. The American journal of tropical medicine and hygiene. 2007 May:76(5):977-82 [PubMed PMID: 17488926]
Level 3 (low-level) evidenceGonzales Santana B, Dalton JP, Vasquez Camargo F, Parkinson M, Ndao M. The diagnosis of human fascioliasis by enzyme-linked immunosorbent assay (ELISA) using recombinant cathepsin L protease. PLoS neglected tropical diseases. 2013:7(9):e2414. doi: 10.1371/journal.pntd.0002414. Epub 2013 Sep 19 [PubMed PMID: 24069474]
Level 3 (low-level) evidenceHassan MM, Saad M, Hegab MH, Metwally S. Evaluation of circulating Fasciola antigens in specific diagnosis of fascioliasis. Journal of the Egyptian Society of Parasitology. 2001 Apr:31(1):271-9 [PubMed PMID: 12557949]
Level 3 (low-level) evidenceSantiago N, Hillyer GV. Antibody profiles by EITB and ELISA of cattle and sheep infected with Fasciola hepatica. The Journal of parasitology. 1988 Oct:74(5):810-8 [PubMed PMID: 3138397]
Level 3 (low-level) evidenceShehab AY, Hassan EM, Basha LM, Omar EA, Helmy MH, El-Morshedy HN, Farag HF. Detection of circulating E/S antigens in the sera of patients with fascioliasis by IELISA: a tool of serodiagnosis and assessment of cure. Tropical medicine & international health : TM & IH. 1999 Oct:4(10):686-90 [PubMed PMID: 10583902]
Level 3 (low-level) evidenceProciv P, Walker JC, Whitby M. Human ectopic fascioliasis in Australia: first case reports. The Medical journal of Australia. 1992 Mar 2:156(5):349-51 [PubMed PMID: 1588869]
Level 3 (low-level) evidenceSezgin O, AltintaÅŸ E, DiÅŸibeyaz S, SaritaÅŸ U, Sahin B. Hepatobiliary fascioliasis: clinical and radiologic features and endoscopic management. Journal of clinical gastroenterology. 2004 Mar:38(3):285-91 [PubMed PMID: 15128078]
Level 2 (mid-level) evidenceTeke M, Önder H, Çiçek M, Hamidi C, Göya C, Çetinçakmak MG, HattapoÄŸlu S, Ülger BV. Sonographic findings of hepatobiliary fascioliasis accompanied by extrahepatic expansion and ectopic lesions. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine. 2014 Dec:33(12):2105-11. doi: 10.7863/ultra.33.12.2105. Epub [PubMed PMID: 25425366]
Koç Z, Ulusan S, Tokmak N. Hepatobiliary fascioliasis: imaging characteristics with a new finding. Diagnostic and interventional radiology (Ankara, Turkey). 2009 Dec:15(4):247-51. doi: 10.4261/1305-3825.DIR.1851-08.2. Epub 2009 Nov 10 [PubMed PMID: 19908182]
Level 3 (low-level) evidenceDias LM, Silva R, Viana HL, Palhinhas M, Viana RL. Biliary fascioliasis: diagnosis, treatment and follow-up by ERCP. Gastrointestinal endoscopy. 1996 Jun:43(6):616-20 [PubMed PMID: 8781945]
Level 3 (low-level) evidenceGraham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001 Jul 1:33(1):1-5 [PubMed PMID: 11389487]
Level 3 (low-level) evidenceVillegas F, Angles R, Barrientos R, Barrios G, Valero MA, Hamed K, Grueninger H, Ault SK, Montresor A, Engels D, Mas-Coma S, Gabrielli AF. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano. PLoS neglected tropical diseases. 2012:6(8):e1720. doi: 10.1371/journal.pntd.0001720. Epub 2012 Aug 7 [PubMed PMID: 22880138]
Level 3 (low-level) evidenceKeiser J, Sayed H, el-Ghanam M, Sabry H, Anani S, el-Wakeel A, Hatz C, Utzinger J, el-Din SS, el-Maadawy W, Botros S. Efficacy and safety of artemether in the treatment of chronic fascioliasis in Egypt: exploratory phase-2 trials. PLoS neglected tropical diseases. 2011 Sep:5(9):e1285. doi: 10.1371/journal.pntd.0001285. Epub 2011 Sep 6 [PubMed PMID: 21909440]
Level 3 (low-level) evidenceRichter J, Freise S, Mull R, Millán JC. Fascioliasis: sonographic abnormalities of the biliary tract and evolution after treatment with triclabendazole. Tropical medicine & international health : TM & IH. 1999 Nov:4(11):774-81 [PubMed PMID: 10588772]
Level 3 (low-level) evidence